Back to Search
Start Over
Durable efficacy of alemtuzumab on clinical outcomes over 5 years in CARE-MS II with most patients free from treatment for 4 years
- Authors :
- Fox, E. J.
Arnold, D. L.
Cohen, J. A.
Coles, A. J.
Hartung, H. P.
Havrdova, E.
Selmaj, K. W.
Margolin, D. H.
Kasten, L.
Panzara, M. A.
Compston, D. A. S.
- Source :
- ResearcherID
Details
- Database :
- OpenAIRE
- Journal :
- ResearcherID
- Accession number :
- edsair.dedup.wf.001..2b0aa901cfecf43e596fd875295df4af